Products

SimplSign

Simple E-Signatures No Subscription

simplsign.app Sales / Proposals, Quotes & E-signature

AI Benchmark
Desktop
Mobile
Monthly visits
<5K
Oct 2026
Public revenue
Undisclosed
No public revenue evidence yet
Entry price
$1/mo
Lowest in categoryNiche median $19/mo
Creators
Roan Schuurman
No social account linked
Launched
10mo ago
2026-01-13 · Est.

Traffic

Last 12 months
Monthly visitsData through Oct 2026
Events1 marketing move

Marketing moves

Launches, search & content, referrals, promotions
  • Launched on Product HuntLaunch

    E-signatures without Account and Subscription - Pay Per Use

    Jan 13 · 10mo agoLaunch page

Traffic sources

Oct 2026

Traffic breakdown

Channels

No data yet

Countries

No data yet

Search

Domain authority —Domain registered 2025-12-08

No search keyword data for this website yet.

Traffic data: Vaneform

Pricing

Per Document
$1.00
Up to 8 signers. · We support PDFs up to 10MB.

Trial: None · Observed 2026-11-07 · Source page

Entry price $1/mo, Lowest in category; “Proposals, Quotes & E-signature” median is $19/mo.View pricing benchmark

Pages & changes

Tracked since 2026-01-13

Key pages

Weekly snapshots
Home
simplsign.app/en Snapshot 2026-11-07

Changes

No pricing, plan, or positioning changes detected since tracking started.

Questions & evidence

How much does SimplSign cost?
Per Document: $1.00. Observed 2026-11-07. Check the source for current billing terms, usage limits and taxes.Source
How much website traffic does SimplSign get?
Vaneform estimates <5K website visits in 2026-10. Visits can include repeat visits; this estimate measures web traffic separately from paying customers or revenue.Source
What is SimplSign and what platforms does it support?
SimplSign is catalogued under Proposals, Quotes & E-signature: Simple E-Signatures No Subscription. Supported platforms: Web.

Related products in this category

Sales / Proposals, Quotes & E-signature

These products share a catalog category. Compare customer tasks, features and deployment requirements before treating them as alternatives.